Global Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight 2016: One of Roche's Three Her2+ Breast Cancer Drugs, Recorded a 15% Sales Increase in the US and a 10% Rise Overall - Research and Markets
DUBLIN, October 21, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight" clinical trials to their offering.
The Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight report gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014.
Trastuzumab or Herceptin is a recombinant DNA derived humanized monoclonal antibody that interferes with the HER2/Neu receptor. It is the most common biological therapy used particularly for breast cancer, against the Her2+ receptor which stands for Human Epidermal Growth Factor Receptor 2-positive. In some cancers, notably certain types of breast cancer, HER2 is over-expressed, and causes cancer cells to reproduce uncontrollably.
Herceptin, one of Roche's three HER2+ breast cancer drugs, recorded a 15% sales increase in the US and a 10% rise overall. Sales were driven by longer duration of treatment in combination with Perjeta, another HER2+ breast cancer treatment from Roche, for both early and advanced breast cancer. China and Brazil also contributed to strong growth in Herceptin sales.
It costs around US$ 70,000 for full course treatment, thus allowing the big blockbuster for Roche with the sales of US$ 6.79 Billion in 2015; it is the drug that remained third best seller after about 15 years on the market. Roche has changed the trade name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately INR 75,000 (US$ 1122) in the Indian market.
Biocon Limited, a pharmaceutical in India had received Marketing Authorization from the Drugs Controller General of India (DCGI) for its biosimilar Trastuzumab being developed jointly with Mylan, for the treatment of Her 2+ metastatic breast cancer. The regulatory approval for biosimilar Trastuzumab in India is the world's first biosimilar version under the brand name of CANMAb.
Key Topics Covered:
1. Herceptin (Trastuzumab) Clinical Insight
1.1 Clinical Introduction
1.2 Company Partnerships & Agreements
1.3 Patent Analysis by Indication
1.4 Brand Names by Country/Region
Herceptin Biosimilars Clinical Insight by Company
2. BOW 040
3. Trastuzumab Biosimilar - ISU Abxis
4. Trastuzumab Biosimilar - Allergan/Amgen
5. Trastuzumab Biosimilar - Alteogen/Cristalia
6. Trastuzumab Biosimilar - AryoGen Biopharma
7. Trastuzumab Biosimilar - Axxo
8. Trastuzumab Biosimilar - Biocad
9. Trastuzumab Biosimilar - BIOCND/Genor Biopharma
10. Trastuzumab Biosimilar - Biocon/Mylan
11. Trastuzumab Biosimilar - Bionovis/The Instituto Vital Brazil
12. Trastuzumab Biosimilar - BioXpress Therapeutics
13. Trastuzumab Biosimilar - Celltrion
14. Trastuzumab Biosimilar - Curaxys
15. Trastuzumab Biosimilar - Dong-A ST/Meiji Seika Pharma
16. Trastuzumab Biosimilar - Dr. Reddy's Laboratories
17. Trastuzumab Biosimilar - Gedeon Richter
18. Trastuzumab Biosimilar - Hanwha Biologics
19. Trastuzumab Biosimilar - Harvest Moon Pharmaceuticals
20. Trastuzumab Biosimilar - Hetero Drugs
21. Trastuzumab Biosimilar - International Biotech Center Generium
22. Trastuzumab Biosimilar - Mabion
23. Trastuzumab Biosimilar - mAbxience
24. Trastuzumab Biosimilar - Nanogen Biopharmaceutical
25. Trastuzumab Biosimilar - Nichi-Iko Pharmaceutical/Aprogen
26. Trastuzumab Biosimilar - Oncobiologics
27. Trastuzumab Biosimilar - Paras Biopharmaceuticals
28. Trastuzumab Biosimilar - Pfizer
29. Trastuzumab Biosimilar - PlantForm Corporation
30. Trastuzumab Biosimilar - Polpharma
31. Trastuzumab Biosimilar - ProBioGen AG/Bio Farma Indonesia
32. Trastuzumab Biosimilar - Reliance Life Sciences
33. Trastuzumab Biosimilar - Samsung Bioepis
34. Trastuzumab Biosimilar - Shanghai CP Guojian Pharmaceutical
35. Trastuzumab Biosimilar - Shanghai Henlius Biotech
36. Trastuzumab Biosimilar - STC Biologics
37. Trastuzumab Biosimilar - Therapeutic Proteins International
38. Trastuzumab Biosimilar - Zydus
39. Trastuzumab Glyco-optimised - Glycotope
40. Trastuzumab Subcutaneous
For more information about this clinical trials report visit http://www.researchandmarkets.com/research/lrq3xm/herceptin
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article